首页> 外文期刊>Journal of oncology pharmacy practice: official publication of the International Society of Oncology Pharmacy Practitioners >Efficacy of bevacizumab and temozolomide therapy in locally advanced, recurrent, and metastatic malignant solitary fibrous tumour: A population-based analysis
【24h】

Efficacy of bevacizumab and temozolomide therapy in locally advanced, recurrent, and metastatic malignant solitary fibrous tumour: A population-based analysis

机译:贝伐单抗和替替唑胺治疗在局部先进,复发性和转移性恶性孤立纤维肿瘤中的疗效:基于群体的分析

获取原文
获取原文并翻译 | 示例
           

摘要

Background Patients with locally advanced, recurrent or metastatic solitary fibrous tumour are often treated with bevacizumab and temozolomide based on the clinical efficacy reported in a case series of 14 patients. Given the rarity of solitary fibrous tumour, large trials are not feasible. We report the efficacy of this regimen based on a population-based analysis. Methods This was a population-based retrospective, multi-centre analysis using patient data from a provincial cancer registry and treatment database. Cases from June 2006 through October 2016 were identified for patients receiving bevacizumab and temozolomide for locally advanced, recurrent or metastatic solitary fibrous tumour or hemangiopericytoma, which is sometimes used to describe tumours arising from the meninges. The primary outcome was overall response rate. Secondary outcomes included time to response, progression free survival and overall survival estimated using the Kaplan-Meier method. Results Fourteen patients were identified: median age 59 (range 44-70), male 78.6%. Diagnoses were solitary fibrous tumour in 10 (71.4%) and hemangiopericytoma in four (28.6%), with metastatic disease in 10 (72.7%) patients. The most common primary sites were meninges in four (28.6%) and pelvis in three (21.4%) patients. The median follow-up was 15.5 months, with median treatment of four months. Overall response rate was 21.4% (no complete response, 3 partial response), with median time to response of four months. Median progression free survival, six-month progression free survival and overall survival were 17 months, 65.0%, and 45 months, respectively. Conclusions Efficacy of bevacizumab and temozolomide in solitary fibrous tumour appeared to be similar to that previously reported. Our findings confirmed that bevacizumab and temozolomide is an effective and tolerated treatment for this patient population.
机译:背景技术患者局部晚期,复发或转移性纤维纤维肿瘤的患者通常基于在14名患者的案例系列中报告的临床疗效进行贝伐单抗和替代唑胺治疗。鉴于孤立纤维肿瘤的罕见,大型试验是不可行的。我们以基于人口的分析报告了这个方案的功效。方法这是一种基于人口的追溯,多中心分析,使用来自省级癌症登记和治疗数据库的患者数据。案件于2006年6月至2016年10月,针对接受贝伐单抗和替代性孤立纤维纤维肿瘤或血管二胞质瘤的患者的患者鉴定出患者,这有时用于描述脑膜引起的肿瘤。主要结果是整体反应率。二次结果包括使用Kaplan-Meier方法估算的响应,进展免费生存和整体生存的时间。结果鉴定了十四名患者:中位数59岁(范围44-70),男性78.6%。诊断在10(71.4%)和血管素瘤中的孤零性纤维肿瘤四(28.6%),10例(72.7%)患者转移疾病。最常见的主要部位在三(21.4%)患者中有四次(28.6%)和骨盆中的脑膜。中位随访时间为15.5个月,中位数治疗四个月。总体反应率为21.4%(无完全答复,3个部分响应),中位时间响应四个月。中位进展自由生存,六个月的进展免费生存和整体生存率分别为17个月,65.0%和45个月。结论贝伐单抗和替代纤维肿瘤中的替替莫唑酯的疗效似乎与先前报道的相似。我们的研究结果证实,Bevacizumab和Temozolomide是对该患者群体的有效和耐受的治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号